中国肿瘤外科杂志
中國腫瘤外科雜誌
중국종류외과잡지
CHINESE MEDICAL DIGEST SURGERY
2015年
4期
226-229
,共4页
ERCC-1%BRCA-1%Survivin%非小细胞肺癌%多西他赛%顺铂
ERCC-1%BRCA-1%Survivin%非小細胞肺癌%多西他賽%順鉑
ERCC-1%BRCA-1%Survivin%비소세포폐암%다서타새%순박
ERCC-1%BRCA-1%Survivin%non-small cell lung cancer%docetaxel%cisplatin
目的：探讨以铂类、紫杉类为基础化疗方案的非小细胞肺癌患者中核苷酸切除修复交叉互补基因(ERCC-1)、乳腺癌敏感蛋白Ⅰ型(BRCA-1)、凋亡抑制基因(survivin)表达及其与预后的关系。方法采用免疫组化( IHC )检测74例以铂类、紫杉类为基础化疗的非小细胞肺癌患者组织标本中ERCC-1、BRCA-1及Survivin蛋白的表达,分析其表达与患者预后的关系。结果(1) ERCC-1表达率60.81%,与患者性别、年龄、分期、病理及吸烟史无关,在化疗有效的患者中ERCC-1高表达率45.45%,在化疗无效的患者中高表达率83.33%(P=0.001)。(2) BRCA-1表达率59.46%,与患者性别、年龄、分期无关,与病理(0.016)及吸烟史(0.002)有关,在化疗有效的患者中BRCA-1高表达率47.33%,在化疗无效的患者中高表达率76.67%(P=0.016)。(3) Survivin表达率51.35%,与患者性别、年龄、分期、病理及吸烟史无关,在化疗有效的患者中 Survivin高表达率40.91%,在化疗无效的患者中高表达率66.67%(P=0.035)。结论 ERCC-1、Survivin低表达,BRCA-1高表达患者能从含铂方案的化疗中获益,提示三者联合检测可以作为非小细胞肺癌患者化疗疗效的预测因素。
目的：探討以鉑類、紫杉類為基礎化療方案的非小細胞肺癌患者中覈苷痠切除脩複交扠互補基因(ERCC-1)、乳腺癌敏感蛋白Ⅰ型(BRCA-1)、凋亡抑製基因(survivin)錶達及其與預後的關繫。方法採用免疫組化( IHC )檢測74例以鉑類、紫杉類為基礎化療的非小細胞肺癌患者組織標本中ERCC-1、BRCA-1及Survivin蛋白的錶達,分析其錶達與患者預後的關繫。結果(1) ERCC-1錶達率60.81%,與患者性彆、年齡、分期、病理及吸煙史無關,在化療有效的患者中ERCC-1高錶達率45.45%,在化療無效的患者中高錶達率83.33%(P=0.001)。(2) BRCA-1錶達率59.46%,與患者性彆、年齡、分期無關,與病理(0.016)及吸煙史(0.002)有關,在化療有效的患者中BRCA-1高錶達率47.33%,在化療無效的患者中高錶達率76.67%(P=0.016)。(3) Survivin錶達率51.35%,與患者性彆、年齡、分期、病理及吸煙史無關,在化療有效的患者中 Survivin高錶達率40.91%,在化療無效的患者中高錶達率66.67%(P=0.035)。結論 ERCC-1、Survivin低錶達,BRCA-1高錶達患者能從含鉑方案的化療中穫益,提示三者聯閤檢測可以作為非小細胞肺癌患者化療療效的預測因素。
목적：탐토이박류、자삼류위기출화료방안적비소세포폐암환자중핵감산절제수복교차호보기인(ERCC-1)、유선암민감단백Ⅰ형(BRCA-1)、조망억제기인(survivin)표체급기여예후적관계。방법채용면역조화( IHC )검측74례이박류、자삼류위기출화료적비소세포폐암환자조직표본중ERCC-1、BRCA-1급Survivin단백적표체,분석기표체여환자예후적관계。결과(1) ERCC-1표체솔60.81%,여환자성별、년령、분기、병리급흡연사무관,재화료유효적환자중ERCC-1고표체솔45.45%,재화료무효적환자중고표체솔83.33%(P=0.001)。(2) BRCA-1표체솔59.46%,여환자성별、년령、분기무관,여병리(0.016)급흡연사(0.002)유관,재화료유효적환자중BRCA-1고표체솔47.33%,재화료무효적환자중고표체솔76.67%(P=0.016)。(3) Survivin표체솔51.35%,여환자성별、년령、분기、병리급흡연사무관,재화료유효적환자중 Survivin고표체솔40.91%,재화료무효적환자중고표체솔66.67%(P=0.035)。결론 ERCC-1、Survivin저표체,BRCA-1고표체환자능종함박방안적화료중획익,제시삼자연합검측가이작위비소세포폐암환자화료료효적예측인소。
Objective To investigate the relationship among expression of ERCC-1,BRCAI,Survivin and prognosis in non-small cell lung cancer treated by platinum,Taxane-based chemotherapy. Methods The protein expression of ERCC-1,BRCA-1 and Survivin were detected by immunohistochemistry(IHC)in 74 patients. The relation between expression level of ERCC-1, BRCA-1, Survivin and prognosis was analyzed. Results ( 1 ) ERCC-1 expression rate was 60. 81%, while gender, age, stage, pathology and history of smoking were irrele-vant. The high expression rate of ERCC-1 was 45. 45% in the patients reveiving chemo and 83. 33% in the in-effective chemotherapy patients(P =0. 001). (2)BRCA-1 expression rate was 59. 46%,while gender, age, stage were irrelevant, but correlation with pathology and history of smoking were relevant. The high expression of BRCA-1 was 47. 33% in the patients reveiving chemo and 76. 67% in the ineffective chemotherapy patients (P=0. 016). (3)Survivin expression rate was 40. 91%, while gender, age, stage, pathology and history of smoking were irrelevant. The high expression of Survivin was 40. 91% in the chemotherapy patients and 66. 67% in the ineffective chemotherapy patients(P=0. 035). Conclusions The expression rate of ERCC-1, BRCA-1 and Survivin may provide important predictive value for chemotherapy in non-small cell lung cancer.
